Barry Greene Seizes CNS Leadership Opportunity As New Sage CEO
Jeff Jonas Remains As Chief Innovation Officer, Board Member
When Greene made the decision to leave Alnylam, he was interested in working with a drug maker treating central nervous system diseases.
